Innovation Achievements
Relying on the core technologies，such as ARMS fluorescent quantitative PCR and multiple fluorescent quantitative PCR, the company has successfully developed 16 molecular diagnostic kits since 2014, and obtained the Class III medical device registration certificate by National Medical Products Administration(NMPA). YZY Med has established a complete solutions in the direction of personalized medication on gene detection for cardiovascular diseases and tumor companion diagnosis. YZY Med has become a leading enterprise, with the detection volume exceeding 1.5 million person/time, ranks the first in domestic market in this subdivision.
AutoanalyzerSystem for Circulating Tumor CellCTCBIOPSY®-A10 and Slide Scanning Imaging System CTCBIOPSY®-D800 developed byYZY Med have obtained the medical device registration certificates, with over30,000 cases of clinical data verification. The solid technical accumulationand adequate clinical data enable the company to maintain the leading positionin the field of liquid biopsy.
The fluorescence in situ hybridization (FISH) Probe Kits developed by the company have been successively launched into the market since 2020. It is believed that with excellent quality and perfect service, we will win the trust and support of most customers.
Intellectual property
As the core competitiveness of an enterprise and the basis for shaping brand value, intellectual property embodies the hard power, long-term development strategy and comprehensive strength of an enterprise. YZY Med attaches great importance to the construction of intellectual property rights, and has achieved obvious results through practical measures. The company has applied for over 110 patents with over 70 patent authorizations, relying on its technological advantages, the company will carry out the layout, navigation and cultivation of high-value patents, thus to continuously improve its R&D strength and intellectual property management level.
Patent wall